Subscribe
clu
clu / iStockphoto.com
10 April 2018Americas

Eli Lilly tries to halt another Cialis generic

Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis (tadalafil).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.
Americas
Eli Lilly settles Cialis patent litigation with generic makers
18 July 2017   Eli Lilly has entered into a settlement agreement with generic companies Teva Pharmaceuticals and Watson Laboratories to resolve pending patent litigation over its drug Cialis.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.
Americas
Eli Lilly settles Cialis patent litigation with generic makers
18 July 2017   Eli Lilly has entered into a settlement agreement with generic companies Teva Pharmaceuticals and Watson Laboratories to resolve pending patent litigation over its drug Cialis.

More on this story

Big Pharma
Eli Lilly defeated as Cialis patent found obvious on appeal
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.
Americas
Eli Lilly settles Cialis patent litigation with generic makers
18 July 2017   Eli Lilly has entered into a settlement agreement with generic companies Teva Pharmaceuticals and Watson Laboratories to resolve pending patent litigation over its drug Cialis.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks